dexamethasone + vincristine + pegylated-asparaginase + cytarabine + cyclophosphamide + methotrexate

This is a multi-agent chemotherapy regimen composed of six drugs—dexamethasone, vincristine, pegylated-asparaginase (PEG-asparaginase), cytarabine, cyclophosphamide, and methotrexate. Each component has a distinct mechanism of action targeting different aspects of leukemic cell survival and proliferation: - **Dexamethasone** is a synthetic glucocorticoid that induces apoptosis in lymphoid cells. - **Vincristine** is a vinca alkaloid that inhibits microtubule formation during mitosis. - **Pegylated-asparaginase** depletes asparagine, an amino acid essential for leukemic cell survival. - **Cytarabine** is an antimetabolite that inhibits DNA synthesis. - **Cyclophosphamide** is an alkylating agent causing cross-linking of DNA strands. - **Methotrexate** inhibits dihydrofolate reductase, blocking folate metabolism and DNA synthesis. This combination regimen has been used primarily in the treatment of acute lymphoblastic leukemia (ALL), both in pediatric and adult populations. It may be referred to by various protocol names depending on the specific study or clinical context but does not have a unique brand name as a fixed combination product. The regimen leverages synergistic effects among its components to maximize anti-leukemic efficacy while managing resistance[1][2][3][8].